Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hotsprings, Arkansas, United States
San Ramon, California, United States
Bay City, Michigan, United States
Fridley, Minnesota, United States
South Euclid, Ohio, United States
Portland, Oregon, United States
San Antonio, Texas, United States
Spanish Fork, Utah, United States
Birmingham, United Kingdom
Cardiff, United Kingdom
Start Date
December 1, 2011
Primary Completion Date
September 1, 2012
Completion Date
September 1, 2012
Last Updated
March 8, 2013
160
ACTUAL participants
CT327 0.05%
DRUG
CT327 0.1%
DRUG
CT327 0.5%
DRUG
Placebo
DRUG
Lead Sponsor
Creabilis SA
NCT04080635
NCT04340076
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03507946